Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold.

Q4 Medicine

JACC. Case reports Pub Date : 2025-09-25 DOI:10.1016/j.jaccas.2025.105531

Jorgo Kostov, Biljana Zafirovska, Sasko Kedev

{"title":"Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold.","authors":"Jorgo Kostov, Biljana Zafirovska, Sasko Kedev","doi":"10.1016/j.jaccas.2025.105531","DOIUrl":null,"url":null,"abstract":"Background: To the best of our knowledge, this is the first reported experience of a patient with late thrombosis of previous Absorb (Abbott Vascular) bioresorbable scaffold (BRS) implantation site, treated with second-generation Magmaris (Biotronik) resorbable magnesium scaffold (RMS).Case summary: A 55-year-old man with a previously implanted Absorb BRS stent presented with a non-ST-elevation myocardial infarction. Coronary angiography showed thrombotic lesion at the BRS stent site. After intravascular optical coherence tomography (OCT) imaging, a decision was made to implant a second-generation RMS stent. OCT follow-up was performed, with excellent long-term results.Discussion: Randomized controlled trials have connected early BRS implantation to a higher rate of stent thrombosis. In recent years, the newer generation RMS has confirmed a good safety profile and long-term patency. The idea behind this treatment was to assess the novel RMS technology with serial OCT imaging.Take-home messages: This case adds new options for the treatment of coronary arteries with novel RMS technology. Intravascular imaging with OCT is essential for optimized treatment and follow-up.","PeriodicalId":14792,"journal":{"name":"JACC. Case reports","volume":" ","pages":"105531"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jaccas.2025.105531","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To the best of our knowledge, this is the first reported experience of a patient with late thrombosis of previous Absorb (Abbott Vascular) bioresorbable scaffold (BRS) implantation site, treated with second-generation Magmaris (Biotronik) resorbable magnesium scaffold (RMS).

Case summary: A 55-year-old man with a previously implanted Absorb BRS stent presented with a non-ST-elevation myocardial infarction. Coronary angiography showed thrombotic lesion at the BRS stent site. After intravascular optical coherence tomography (OCT) imaging, a decision was made to implant a second-generation RMS stent. OCT follow-up was performed, with excellent long-term results.

Discussion: Randomized controlled trials have connected early BRS implantation to a higher rate of stent thrombosis. In recent years, the newer generation RMS has confirmed a good safety profile and long-term patency. The idea behind this treatment was to assess the novel RMS technology with serial OCT imaging.

Take-home messages: This case adds new options for the treatment of coronary arteries with novel RMS technology. Intravascular imaging with OCT is essential for optimized treatment and follow-up.

查看原文本刊更多论文

新型可吸收镁支架治疗第一代生物可吸收支架部位晚期血栓形成。

背景：据我们所知，这是首例报道的患者既往的吸收（雅培血管）生物可吸收支架（BRS）植入部位晚期血栓形成，使用第二代Magmaris （Biotronik）可吸收镁支架（RMS）治疗的病例。病例总结：一名55岁男性，先前植入了吸收BRS支架，表现为非st段抬高型心肌梗死。冠状动脉造影显示BRS支架部位血栓形成。在血管内光学相干断层扫描（OCT）成像后，决定植入第二代RMS支架。进行OCT随访，长期效果良好。讨论：随机对照试验表明早期BRS植入与支架血栓形成率较高有关。近年来，新一代RMS已被证实具有良好的安全性和长期通畅性。这种治疗背后的想法是通过连续OCT成像来评估新的RMS技术。带回家的信息：这个病例为冠状动脉治疗提供了新的选择，新的RMS技术。OCT血管内成像对于优化治疗和随访至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊